Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia-Reference-Cited by-同舟云学术

Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia

Published:2019-03-16 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ansari Saqib H¹,Lassi Zohra S²,Khowaja Salima M³,Adil Syed Omair³,Shamsi Tahir S⁴

Affiliation:

1. National Institute of Blood Disease & Bone Marrow Transplant; Department of Pediatric Hematology and Oncology; ST 2/A Block 17 Gulshan-e-Iqbal, KDA Scheme 24 Karachi Sindh Pakistan 75300

2. The University of Adelaide; The Robinson Research Institute; Adelaide South Australia Australia 5005

3. Omair Sana Foundation; Research Department; Flat B25, Al-Qayam Housing Society Al-fred Street, Garden West Karachi Sindh Pakistan

4. National Institute of Bone Disease & Bone Marrow Transplant; ST 2/A Block 17 Gulshan-e-Iqbal, KDA Scheme 24 Karachi Sindh Pakistan 75300

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012064.pub2/epdf/full

Reference37 articles.

1. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening;Alebouyeh;Annals of Hematology,2004

2. Letter to the Editor. Successful use of hydroxyurea in β-thalassemia major;Arruda;New England Journal of Medicine,1997

3. Hydroxyurea treatment in transfusion-dependent β-thalassemia patients;Bordbar;Iranian Red Crescent Medical Journal,2014

4. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia;Bradai;Blood,2003

5. Decreases transfusion need associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia;Bradai;Transfusion,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype;Nature Communications;2023-10-06

2. CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia;Thalassemia Reports;2023-02-06

3. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias;Cochrane Database of Systematic Reviews;2023-01-13

4. Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia;Blood Advances;2022-12-27

5. Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan;Cureus;2022-07-09